Puma Biotechnology, INC Form 4 insider transactions

Puma Biotechnology, Inc. Director Allison Dorval was granted 27,000 Restricted Stock Units (RSUs) on June 11, 2025, increasing her beneficial ownership to 87,000 shares.

Puma Biotechnology, Inc. director Brian M. Stuglik was granted 27,000 Restricted Stock Units (RSUs) on June 11, 2025, increasing his beneficial ownership to 103,058 shares.

Puma Biotechnology, Inc. Director Troy Edward Wilson reported the acquisition of 27,000 shares of common stock through a Restricted Stock Unit grant on June 11, 2025.

Puma Biotechnology, Inc. Director Alessandra Cesano was granted 27,000 shares of common stock in the form of Restricted Stock Units on June 11, 2025, increasing her total beneficial ownership to 81,000 shares.

Chief Financial Officer of Puma Biotechnology, Maximo F. Nougues, reports acquisition of restricted stock units and stock options.

Jeffrey Jerome Ludwig, Chief Commercial Officer of Puma Biotechnology, acquired shares and stock options on February 7, 2025, according to a recent SEC filing.

Douglas M. Hunt, Senior Vice President of Regulatory Affairs at Puma Biotechnology, reports acquisition of restricted stock units and stock options, along with disposition of common stock.

Alan Auerbach, CEO of Puma Biotechnology, reports the acquisition of common stock and stock options, signaling changes in his beneficial ownership.

Puma Biotechnology's Chief Financial Officer, Maximo F. Nougues, sold 10,227 shares of common stock at an average price of $3.1517 per share on January 2, 2025, under a pre-arranged 10b5-1 trading plan.

Puma Biotechnology's Chief Commercial Officer, Jeffrey Jerome Ludwig, sold 9,437 shares of common stock at an average price of $3.1517 per share under a pre-arranged 10b5-1 trading plan.

Douglas M. Hunt, Senior Vice President of Regulatory Affairs at Puma Biotechnology, sold 8,633 shares of common stock at an average price of $3.1517 per share under a pre-arranged 10b5-1 trading plan.

Puma Biotechnology's CEO, Alan Auerbach, sold 33,841 shares of common stock at an average price of $3.1517 per share on January 2, 2025, under a pre-arranged 10b5-1 trading plan.

Director Michael Miller sold 23,358 shares of Puma Biotechnology (PBYI) at an average price of $3.4877 on August 12, 2024.

Puma Biotechnology's CFO, Maximo F. Nougues, sold 4,156 shares of common stock at an average price of $3.7011 on July 17, 2024, under a pre-arranged 10b5-1 trading plan.

Jeffrey Jerome Ludwig, Chief Commercial Officer of Puma Biotechnology, sold 2,598 shares of common stock at an average price of $3.7011 under a pre-arranged 10b5-1 trading plan.

Douglas M. Hunt, Senior Vice President of Regulatory Affairs at Puma Biotechnology, sold 3,637 shares of common stock at an average price of $3.7011 under a pre-arranged 10b5-1 trading plan.

Alan Auerbach, CEO of Puma Biotechnology, sold 21,920 shares of common stock at an average price of $3.7011 on July 17, 2024, under a pre-existing 10b5-1 trading plan.

Maximo Nougues, CFO of Puma Biotechnology, sold 5,295 shares of common stock at an average price of $3.2685 under a pre-arranged 10b5-1 trading plan.

Jeffrey Jerome Ludwig, Chief Commercial Officer of Puma Biotechnology, sold 6,051 shares of common stock at an average price of $3.2685 on July 2, 2024, under a pre-arranged 10b5-1 trading plan.

Douglas M. Hunt, Senior Vice President of Regulatory Affairs at Puma Biotechnology, sold 4,349 shares of common stock at an average price of $3.2685 on July 2, 2024, under a pre-arranged 10b5-1 trading plan.

Alan Auerbach, CEO of Puma Biotechnology, sold 18,885 shares of common stock on July 2, 2024, under a pre-arranged 10b5-1 trading plan.

Director Troy Wilson reports acquisition of 27,000 shares of Puma Biotechnology stock through restricted stock units.

Director Brian M. Stuglik reports acquisition of 27,000 shares of Puma Biotechnology common stock on June 18, 2024.

Adrian Senderowicz, a director of Puma Biotechnology, acquired 27,000 shares of common stock on June 18, 2024.

Director Michael Patrick Miller acquired 27,000 shares of Puma Biotechnology common stock on June 18, 2024, as part of a restricted stock unit grant.

Director Jay M. Moyes reports acquiring 27,000 shares of Puma Biotechnology, Inc. common stock on June 18, 2024.

Director Allison Dorval reports acquisition of 27,000 shares of Puma Biotechnology stock and disposal of 60,000 shares.

Director Alessandra Cesano reported the acquisition of 27,000 shares of Puma Biotechnology common stock and the disposal of 54,000 shares on June 18, 2024.

Director Troy Wilson sold 27,000 shares of Puma Biotechnology (PBYI) common stock on June 13, 2024, at a weighted average price of $3.3297.

Brian M. Stuglik, a director at Puma Biotechnology, sold 9,900 shares of common stock at an average price of $3.3867 on June 13, 2024, under a pre-arranged 10b5-1 trading plan.